Welcome to our dedicated page for Prenetics Global SEC filings (Ticker: PRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Prenetics Global's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Prenetics Global's regulatory disclosures and financial reporting.
Prenetics Global Limited closed a $1 billion growth financing arrangement with General Catalyst’s Customer Value Fund to scale its IM8 wellness brand. The facility can finance up to 70% of IM8’s marketing spend by monthly customer cohort, with General Catalyst receiving a capped share of cohort income until a fixed multiple is repaid.
No equity, warrants, or convertible instruments are issued, there is no fixed maturity or financial covenants, and recovery is limited to revenue from funded cohorts. The arrangement is classified as a financial liability, with the return component recorded as interest expense, leaving gross margin and operating expense classification unchanged. Prenetics reports approximately $139.7 million in combined cash, investments, and escrow and no debt as of May 31, 2026.
IM8 is described as the fastest-growing premium supplement brand, having delivered over 50 million servings and currently about 200,000 servings daily across 43 markets. IM8 generated preliminary unaudited June 2026 revenue of about $17 million, and FY 2026 IM8 revenue guidance has been raised to $210–220 million from $190–210 million. FY 2025 IM8 revenue was $60 million, and management expects IM8 to reach $300 million in annualized run-rate revenue by year-end 2026 and at least $400 million in 2027 revenue. Across 248,536 customers, every $1 of customer acquisition spend has generated $1.44 in cumulative gross profit on a blended basis.
Prenetics Global Ltd reported that officer Brian J. Rosin, CFO of IM8 (US) LLC, beneficially owns 56,851 Restricted Stock Units (RSUs) under the company’s 2022 Share Incentive Plan. Each RSU represents a contingent right to receive one Class A Ordinary Share, par value $0.0015 per share. Of these, 18,950 RSUs vest on May 14, 2027, another 18,950 RSUs vest in four equal tranches on August 14, 2027, November 14, 2027, February 14, 2028 and May 14, 2028, and the remaining 18,951 RSUs vest in four equal tranches on August 14, 2028, November 14, 2028, February 14, 2029 and May 14, 2029, in each case subject to continued service. Upon vesting, the RSUs are settled and delivered in shares at an exercise price of $0.0000 per share.
Prenetics Global Ltd director Hudson Blake Leogrande acquired 2,000 Class A Ordinary Shares through the settlement of vested Restricted Stock Units. These RSUs were granted under the company’s 2022 Share Incentive Plan and each unit converts into one Class A Ordinary Share.
After the transaction, Leogrande directly holds 2,000 Class A Ordinary Shares, while 22,004 Restricted Stock Units remain outstanding. The vesting and settlement reflect routine equity compensation rather than open-market buying or selling.
Prenetics Global Limited filed an amended annual report to add audited 2025 financial statements for its equity‑method investee Insighta Holdings Limited, after determining Insighta was significant under SEC Regulation S‑X Rule 3‑09.
Insighta reported 2025 revenue of HK$573,247, up from HK$244,218 in 2024, mainly from diagnostics services and laboratory testing kits. Profit for the year rose to HK$5,804,192, helped by other income of HK$27,896,174, largely bank interest. As of December 31, 2025, Insighta held HK$561.2 million in bank deposits with more than three months to maturity and HK$61.0 million in cash and cash equivalents, against total liabilities of only HK$6.5 million. Total assets were HK$636.1 million and equity HK$629.6 million, with no income tax expense recorded for the year.
Prenetics Global Ltd director Cheng Yin Pan, through wholly owned entity M13 Capital Management Holdings Limited, exercised vested Restricted Stock Units into ordinary shares. On June 15, 2026, 15,873 RSUs converted into 15,873 Class A Ordinary Shares at a price of $0.0000 per share.
After the transaction, M13 Capital Management Holdings Limited held 59,051 Class A Ordinary Shares indirectly and 6,406 RSUs remained outstanding. This was a compensation-related RSU settlement rather than an open-market purchase or sale.
Prenetics Global Ltd director David Vanderveen exercised equity awards and received additional shares as part of his departure from the board. On June 15, 2026, 6,944 Class A Ordinary Shares were issued and delivered upon settlement of vested Restricted Stock Units granted under the company’s 2022 Share Incentive Plan.
Each RSU represents a right to receive one Class A Ordinary Share, and a derivative entry in the filing shows 8,681 RSUs tied to the same underlying shares. Any remaining unvested RSUs were forfeited in connection with Vanderveen’s termination of service as director. Following these settlements, he directly holds 45,249 Class A Ordinary Shares.
Prenetics Global Ltd director Leogrande Hudson Blake reported an initial holding of 24,004 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one Class A Ordinary Share at an exercise price of $0.0000 per share. The 24,004 RSUs vested on June 4, 2026 and, subject to continued service, will be settled in shares through 12 equal monthly installments beginning July 4, 2026, with the full balance delivered by June 4, 2027.
Prenetics Global Limited reported strong growth for Q1 2026 while remaining loss-making. Revenue from continuing operations reached $36.0 million, with its IM8 nutrition brand contributing $33.8 million, up 23.1% from Q4 2025 and nearly six times Q1 2025 IM8 revenue.
Gross profit was $23.3 million, but loss from operations was $8.9 million and adjusted EBITDA showed a loss of $5.6 million. The total loss of $23.1 million was driven mainly by non‑cash items: an unrealized fair value loss on digital assets of about $9.8 million and an $8.0 million fair value loss on warrant liabilities.
IM8 momentum has accelerated into Q2 2026, with May monthly revenue of about $16.7 million, implying annualized recurring revenue of roughly $200 million. Management raised full‑year 2026 IM8 revenue guidance to $190–210 million and guided Q2 2026 revenue to $46–48 million, mostly from IM8. Prenetics also completed a full divestiture of digital assets for $41.3 million, held cash of $56.0 million as of March 31, 2026, and executed about $19 million of share repurchases under a $40 million program, while remaining debt‑free.
Prenetics Global Limited reports a board change and highlights rapid growth at its IM8 health brand. Director David Vanderveen resigned effective June 4, 2026, and the company appointed Hudson Leogrande, Founder and CEO of Comfrt, as an independent director. With his appointment, three of Prenetics’ four directors are independent under Nasdaq rules. IM8 has reached $100 million in annualized recurring revenue in 11 months and is projected to reach $250 million to $300 million ARR by the end of 2026. Prenetics recently raised its full-year 2026 IM8 revenue guidance to $190 million to $210 million and plans to apply Comfrt’s TikTok and Meta social commerce playbook to accelerate IM8’s expansion.
Cheng Yin Pan reported acquisition or exercise transactions in this Form 4 filing.
Prenetics Global Ltd director Cheng Yin Pan, through wholly owned entity M13 Capital Management Holdings Ltd, received a grant of 6,406 Restricted Stock Units under the company’s 2022 Share Incentive Plan. Each RSU represents the right to receive one Class A Ordinary Share.
The 6,406 RSUs are scheduled to vest on May 17, 2027, subject to continued service. After this grant, indirect holdings reported for this award total 22,279 RSUs. Vested RSUs are not automatically settled; delivery of Class A Ordinary Shares occurs at Cheng Yin Pan’s election in line with the company’s insider trading policy.